ERBB2 and neoplasm: The authors concluded that inhibition of the EGFR/HER2 signalling pathway suppressed PD-L1 and released immunosuppressive cytokines, suggesting that EGFR/HER2 inhibition may create a more favourable milieu for tumour immunotherapy [181].